Cochrane Review Group

Gut

172 systematic reviews in Gut ask 2,395 questions. 17.5% have no studies to answer them, 34.3% rest on very low certainty evidence and 20.6% reach moderate or high certainty.

Reviews

172

Questions

2,395

current versions

No studies

17.5%

Moderate or high

20.6%

No studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Gut

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Infliximab vs purine analogues Loss of clinical response · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Withdrawal due to adverse events · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Serious adverse events (at 2 years) · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.79 [0.37, 1.68]	1 study · 140 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Clinical relapse (at 22 weeks, CDAI > 150) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 1.01 [0.65, 1.57]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.94 [0.7, 1.25]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Withdrawal due to adverse events (at 30 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.77 [0.3, 1.97]	1 study · 53 participants	Very low
Infliximab vs placebo Loss of clinical response (at 32 weeks, less than 70 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.59 [0.37, 0.96]	1 study · 73 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Loss of clinical response (at 56 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.68 [0.29, 1.59]	1 study · 73 participants	Very low
Infliximab vs adalimumab Withdrawal due to adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.1 [0.01, 0.72]	1 study · 73 participants	Very low
Infliximab vs adalimumab Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.09 [0.01, 1.54]	1 study · 73 participants	Very low

Reviews 172

Short‐term treatment with proton pump inhibitors, H2‐receptor antagonists and prokinetics for gastro‐oesophageal reflux disease‐like symptoms and endoscopy negative reflux disease

Sigterman, KE, van Pinxteren, B, et al. · Cochrane Database of Systematic Reviews · 2013

Gut

Thinnest evidence

Reviews 172

Short‐term treatment with proton pump inhibitors, H2‐receptor antagonists and prokinetics for gastro‐oesophageal reflux disease‐like symptoms and endoscopy negative reflux disease

Laparoscopic repair for perforated peptic ulcer disease

Chinese herbal medicines for induction of remission in advanced or late gastric cancer

Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding

Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Optimum duration of regimens for Helicobacter pylori eradication

Somatostatin analogues for pancreatic surgery

Post‐surgical chemotherapy versus surgery alone for resectable gastric cancer

Prophylactic gastrojejunostomy for unresectable periampullary carcinoma

Opioids for acute pancreatitis pain

Early versus delayed laparoscopic cholecystectomy for acute gallstone pancreatitis

Rectal 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis

Acupuncture for treatment of irritable bowel syndrome

Screening for oesophageal cancer

Curcumin for maintenance of remission in ulcerative colitis

Early routine endoscopic retrograde cholangiopancreatography strategy versus early conservative management strategy in acute gallstone pancreatitis

Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents

Psychological interventions for treatment of inflammatory bowel disease

Sargramostim (GM‐CSF) for induction of remission in Crohn's disease

Enteral versus parenteral nutrition for acute pancreatitis

Recombinant human interleukin 10 for induction of remission in Crohn's disease

Red cell transfusion for the management of upper gastrointestinal haemorrhage